Reflecting on the Year in Cancer Care: Progress, Hope, and What’s Ahead

As we close out the year, it’s a good time to reflect on how far cancer care has come, and what’s still ahead. The field of oncology is evolving rapidly, and patients, caregivers, and care teams alike benefit from understanding the progress, the hope it brings, and the directions we’re heading. 

Major Advances in Treatment and Research

  • More new therapies approved

Between July 1, 2024, and June 30, 2025, the American Association for Cancer Research (AACR) reports that the U.S. Food and Drug Administration approved 20 new anticancer therapeutics and two new devices. One device for treating lung cancer and one for cervical cancer screenings, along with expanding the use of 8 previously approved anticancer therapeutics. 

  • Survival is improving

The number of cancer survivors in the U.S. is projected to reach approximately 18.6 million this year, with an expected rise to more than 22 million by 2035. 

  • Precision medicine and immunotherapy are expanding

Precision oncology, molecular profiling, and immunotherapy are offering more personalized treatment options, changing how we think about “one-size-fits-all.”

Advances in artificial intelligence, machine learning, and multimodal data are helping create smarter diagnostics and treatment planning. 

Why Hope Matters, and What It Means for Patients

Hope isn’t just an emotion; it represents tangible change in care, more treatment options, and better outcomes. For patients and families, this means earlier detection, fewer side-effects, improved quality of life, and greater involvement in decisions. At our community oncology practice, hope translates into our daily work to bring advanced care closer to home and make it personal and meaningful.

Challenges Still to Overcome

While progress is real, there are still important gaps and issues:

  • Disparities in care access remain a concern. Certain racial, minority, and medically underserved populations continue to bear a disproportionate burden of cancer.
  • Clinical trial enrollment and availability still limit how many patients can access emerging treatments. 
  • Preventative care and early detection still lag behind in some cancer types and populations, meaning many cancers are still diagnosed late. 
  • Sustainable research funding and resource allocation will be vital to maintain momentum.

What’s Ahead: What to Watch For

Looking into 2026 and beyond, here are some key areas that may shape cancer care:

  • Broader use of liquid biopsies and multi-cancer early detection tests, helping find cancer earlier when treatment is more effective.
  • Expansion of personalized vaccines and cellular therapies, moving beyond blood cancers into more solid tumors.
  • Greater integration of digital tools, telehealth and remote monitoring, allowing more patient-centric care closer to home.
  • Continued emphasis on survivorship and quality of life measures, ensuring patients live well after treatment.
  • Local access to advanced care and clinical trials, especially through community practices partnering with academic centers.

How PCSRI Supports You

At PCSRI, we are committed to offering the latest in cancer care, right here in Pennsylvania. Whether you are newly diagnosed, in treatment, or in survivorship, our care team strives to bring progress, hope, and partnership to your journey. We believe in keeping you informed about new treatments, supporting your access to care, and empowering you to take an active role. 

Final Thoughts

This past year has been a milestone in many ways for cancer care. For you and your loved ones it means more hope, more possibilities, and more reasons to stay engaged in your care. As we move forward together, let’s embrace progress, stay informed about what’s ahead, and remember that every treatment change, every clinical trial, and every patient story contributes to the bigger picture of better care for all. 

More Articles